Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 14/20 | 0.77 |
| ▸ | MAOA | P21397 | 2/20 | 0.54 |
| ▸ | MAOB | P27338 | 2/20 | 0.54 |
| ▸ | PTPN2 | P17706 | 2/20 | 0.53 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.47 |
| ▸ | BCHE | P06276 | 1/20 | 0.47 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.47 |
| ▸ | ACHE | P22303 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | POLB | P06746 | 2/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31292056 | 1.00 | PTPN1 (0.77) | PTPN1MAOAMAOBPTPN2ALOX15 | |
| SCHEMBL5377350 | 0.87 | PTPN1 (1.00) | PTPN1MAOAMAOBPTPN2ALOX15 | |
| SCHEMBL29956322 | 0.79 | PTPN1 (0.61) | PTPN1MAOAMAOBPTPN2ALDH1A1 | |
| SCHEMBL29952420 | 0.79 | ALDH1A1 (0.68) | PTPN1MAOAMAOBPTPN2ALDH1A1 | |
| SCHEMBL911098 | 0.79 | ALDH1A1 (0.68) | PTPN1MAOAMAOBPTPN2ALDH1A1 | |
| SCHEMBL18021729 | 0.79 | ALOX15 (0.49) | PTPN1MAOBALOX15ALDH1A1POLB | |
| SCHEMBL26611784 | 0.79 | PTPN1 (0.66) | PTPN1MAOAMAOBPTPN2ALOX15 | |
| SCHEMBL29952901 | 0.79 | PTPN1 (0.77) | PTPN1MAOAMAOBPTPN2ALOX15 | |
| SCHEMBL29757393 | 0.79 | PTPN1 (0.66) | PTPN1MAOAMAOBPTPN2ALOX15 | |
| SCHEMBL11869457 | 0.76 | PTPN1 (0.65) | PTPN1MAOAMAOBPTPN2ALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250269043-A1 | TARGETED BIFUNCTIONAL DEGRADERS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2025-08-28 | — | — | US | disclosed |
| EP-4493221-A2 | TARGETED BIFUNCTIONAL DEGRADERS | Yale University (US) | 2025-01-22 | — | — | EP | disclosed |
| WO-2023178199-A2 | TARGETED BIFUNCTIONAL DEGRADERS | YALE UNIVERSITY (US) | 2023-09-21 | — | — | WO | disclosed |
| CN-115433200-B | Tetracyclic compound containing chroman-4-one structure, synthesis method and application | 广州大学 | 2023-07-21 | — | — | CN | disclosed |
| US-20230087994-A1 | TARGETED BIFUNCTIONAL DEGRADERS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2023-03-23 | — | — | US | disclosed |
| CN-115433200-A | Tetracyclic compound containing chroman-4-one structure, synthetic method and application | 广州大学 | 2022-12-06 | — | — | CN | disclosed |
| CN-115315272-A | Targeting difunctional degradation agent | 耶鲁大学 | 2022-11-08 | — | — | CN | disclosed |
| US-20220340893-A1 | BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | NUEVOLUTION A/S (DK) | 2022-10-27 | — | — | US | disclosed |
| EP-4041262-A1 | TARGETED BIFUNCTIONAL DEGRADERS | Yale University (US) | 2022-08-17 | — | — | EP | disclosed |
| WO-2021072269-A1 | TARGETED BIFUNCTIONAL DEGRADERS | YALE UNIVERSITY (US) | 2021-04-15 | — | — | WO | disclosed |
| US-20050197382-A1 | Indolinone combinatorial libraries and related products and methods for the treatment of disease | SUGEN, INC. | 2005-09-08 | — | — | US | disclosed |
| US-20030229108-A1 | Barbituric acid analogs as therapeutic agents | NOVUSPHARMA S.P.A. (IT) | 2003-12-11 | — | — | US | disclosed |
| CN-1433312-A | Barbituric acid analogs as therapeutic agents | NOWISS MEDICINE S P A (IT) | 2003-07-30 | — | — | CN | disclosed |
| EP-1305026-A2 | BARBITURIC ACID ANALOGS AS THERAPEUTIC AGENTS | Novuspharma S.p.A. (IT) | 2003-05-02 | — | — | EP | disclosed |
| US-6506763-B2 | Useful in prevention and treatment of protein kinase related disorders such as cancer | SUGEN, INC. | 2003-01-14 | — | — | US | disclosed |
| WO-2001093841-A2 | BARBITURIC ACID ANALOGS AS THERAPEUTIC AGENTS | NOVUSPHARMA S.P.A. (IT) | 2001-12-13 | — | — | WO | disclosed |
| US-6133305-A | PREVENTION AND TREATMENT OF PROTEIN KINASE RELATED DISORDERS SUCH AS CANCER | SUGEN, INC. (US) | 2000-10-17 | — | — | US | disclosed |
| WO-2000053313-A2 | LANTHANIDE CATALYSTS FOR SYNTHESIS OF COMPOUNDS AND COMBINATORIAL LIBRARIES | ARQULE, INC. (US) | 2000-09-14 | — | — | WO | disclosed |
| US-4098799-A | ANTIALLERGENS, HYPERACIDITY | WARNER-LAMBERT COMPANY (US) | 1978-07-04 | — | — | US | disclosed |
| US-4008252-A | ANTIALLERGENS, ANTIHYPERACIDITY | WARNER-LAMBERT COMPANY (US) | 1977-02-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250269043-A1 | TARGETED BIFUNCTIONAL DEGRADERS | SMURF2, SMURF1, MDM2 | PTPN1 994/4885MAOA 621/4885MAOB 1192/4885 |
| US-20030229108-A1 | Barbituric acid analogs as therapeutic agents | HIF1AN, HIF1A, VHL | PTPN1 3627/4885MAOA 1754/4885MAOB 2446/4885 |
| US-20230087994-A1 | TARGETED BIFUNCTIONAL DEGRADERS | SMURF2, SMURF1, SSB | PTPN1 971/4885MAOA 718/4885MAOB 1356/4885 |
| US-20050197382-A1 | Indolinone combinatorial libraries and related products and methods for the treatment of disease | FRK, PTK2, DSTYK | PTPN1 882/4885MAOA 1231/4885MAOB 867/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.